Our formulation manufacturing facility is located in Aurangabad, India, and is benchmarked to the highest international quality standards. With state-of-the-art manufacturing facilities, we aim to be one of the most valued integrated Pharmaceutical Companies offering end-to-end solutions for CMO and New product developments.
Our key focus is on the core segments of lifestyle therapies such as Anti-Diabetics, Antihypertensives, CNS acting drugs, Gastrointestinals, Anti-gouts etc. We have a capacity of 2 Billion tablets per annum with full automation controls in multiple phases offering batch sizes with respect to granulation capacity up to 4000 kg per batch. Additionally, 8 Billion tablets capacity facility is under completion and will be operational by Q4 2021.
We also have a completely dedicated small-batch manufacturing area (SBM) for low volume niche products offering batch sizes with respect to granulation capacity as 11 kg to 33.5 kg.
Our facility is EU GMP and TGA approved. USFDA audit has been triggered.
We have a renowned and fully equipped R&D facility at Aurangabad utilizing the latest laboratory equipment compliant to 21-CFR. We have a highly skilled and experienced team of scientists for developing generic equivalents and complex products in-house.
Our new and futuristic R&D center, in Navi Mumbai, further augments our innovative programs for enhanced production.
We have been associated with big generic companies for offering the best to end-users and stakeholders. We work in close coordination with our customers for leveraging core competencies. Many new projects for Finished Dosage are under various stages of development & regulatory submissions.